The expected milestones are as follows :2QCY09 Release of...

The expected milestones are as follows :

2QCY09 Release of 16-week data from first Phase III ATC clinical trial
4QCY09 Phase IIb 144 week final data analysis
2QCY10 Complete enrolment of first Phase III study
4QCY10 Phase III (first trial) week 24 data available
1QCY11 Potential filing from 24 week data in some jurisdictions

ATC has qualifies for fast track approval which means the FDA can approve it for marketing on the basis of preliminary evidence, without waiting until the trial completes. Hence the possibility of filing based on the 24 week results.